ACADIA Pharmaceuticals(US:ACAD) Prnewswire·2025-10-03 16:45Core Insights - Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. regarding potential securities fraud or unlawful business practices [1] - On September 24, 2025, Acadia announced that its Phase 3 COMPASS PWS trial for intranasal carbetocin (ACP-101) did not show statistically significant improvement over placebo, leading to a decision not to pursue further investigation of the drug [1] - Following the announcement, Acadia's stock price dropped by $2.34, or 9.92%, closing at $21.26 per share [1] Company Overview - ACADIA Pharmaceuticals Inc. is involved in the development of treatments for central nervous system disorders, with a focus on innovative therapies [1] - The company’s recent trial results have raised concerns among investors regarding its future prospects and management decisions [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has successfully recovered multimillion-dollar damages for class members in the past, indicating its capability in handling such investigations [2]